Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Negative clinical history for measles, mumps, rubella, varicella, and zoster~Exclusion Criteria:~* Received any measles, mumps, rubella, or varicella vaccine, either alone or in any combination at any time prior to the study, or is anticipated to receive any of these vaccines outside of study protocol, either alone or in any combination, during the study~* Received immune globulin, a blood transfusion or blood-derived products (does not include autologous blood/blood products) within 5 months (150 days) prior to any dose of the study vaccines or plans to receive these products while enrolled in this study~* Exposed to measles, mumps, rubella, varicella, or zoster within 4 weeks prior to the study vaccination~* Any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity, including that resulting from steroid use or other immunosuppressive therapy~* Received 1) systemic immunomodulatory steroids \[greater than the~equivalent of 2 mg/kg total daily dose of prednisone\] within 3 months prior to~entering the study, or 2) any dose of systemic immunomodulatory steroids within~7 days prior to entering study, or 3) is expected to require systemic immunomodulatory steroids through the course of the study~* History of allergy or anaphylactoid reaction to gelatin, sorbitol, neomycin, egg proteins (eggs or egg products), chicken proteins, or any component of the study vaccines~* Received salicylates (eg, aspirin or aspirin-containing products) within 14 days prior to study vaccination~* Diagnosis of an active neurological disorder. Enrollment may be considered~when the disease process has been stabilized~* History of seizure disorder, including single febrile seizure~* Diagnosis of active untreated tuberculosis~* History of thrombocytopenia~* Born to a human immunodeficiency virus (HIV) infected mother

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- MMRV (AMP) (Type: EXPERIMENTAL): Participants received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)
- MMRV (2006 process) (Type: ACTIVE_COMPARATOR): Participants received two 0.5 mL subcutaneous injections of MMRV vaccine made with the 2006 manufacturing process

Based on this trial design, predict the completion outcome and termination type (if applicable).